TriangleZanzalintinib (NCT07428616)
Zanzalintinib trial for Meningioma (NCT07428616). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with grade 1, 2 or 3 meningioma that has returned or progressed after standard treatment, or when that treatment is unsuitable. Prior radiation is required unless contraindicated; patients needing local treatment are excluded.
The idea: take zanzalintinib once daily. It blocks proteins involved in tumor growth and new blood-vessel formation. Researchers measure tumor response on scans and monitor side effects.
This phase 2 study plans 100 patients. Exelixis sponsors the study; 20 US locations list recruitment.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.